ERBB2 and breast cancer: Inhibition of miR-21 selectively inhibited the survival, proliferation and oncogenic potential of HER2-positive breast cancer cells carrying the 17q23 amplicon and suppressed the emergence and spread of trastuzumab resistance in breast cancer cells (50).